- Allscripts has agreed to acquire ZappRx for an undisclosed sum.
- ZappRx has developed a specialty medication tracking and management system.
- With the deal, MDRX gains access to data for its Veradigm unit and continues its diversification push.
- Looking for a community to discuss ideas with? IPO Edge features a chat room of like-minded investors sharing investing ideas and strategies. Start your free trial today »
Quick Take
Allscripts (NASDAQ:MDRX) announced it has agreed to acquire ZappRx for an undisclosed amount.
ZappRx has developed a digital specialty medication prescription and prior authorization platform.
MDRX is acquiring ZappRx to expand its access to data and related capabilities for its Veradigm business segment.
Target Company
Boston, Massachusetts-based ZappRx was founded in 2012 to enable healthcare providers, pharmacists, and patients to digitally interact with one another to fill a specialty medical prescription.
Management is headed by co-founder and CEO Zoë Barry, who is also an advisor at Remy and Boston Microfluidics.
Below is an overview video of the company's platform:
Source: ZappRx
Features of ZappRx's platform include digital initiation of the prescription enrollment process, the ability to populate information for a patient at the same time as prescribing a specialty drug, obtaining digital patient consent, as well as prescription status checking.
Company partners include:
- Teva Respiratory (TEVA)
- Bayer (OTCPK:BAYZF)
- Genentech (OTCQX:RHHBY)
Source: ZappRx
Investors have invested at least $41 million in the company and include GV (NASDAQ:GOOG) (NASDAQ:GOOGL), SR One, Atlas Venture, Qiming Venture Partners, and individual investors. Source: Crunchbase
